Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Updated results of ALTER-C002: Anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer.
Authors
Ke-Feng Ding
Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China;
Ke-Feng Ding , Yue Liu , Qian Xiao , Jinjie He , Hanguang Hu , Jinlin Du , Yuping Zhu , Jiaqi Chen , Zhuo Liu , Jianping Wang , Lifeng Sun , Dong Xu , Jun Li , Xiujun Liao , Jianwei Wang , Yibo Cai , Cheng Cai , Zhekang Jin , Ying Yuan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04080843
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 138)
DOI
10.1200/JCO.2023.41.4_suppl.138
Abstract #
138
Poster Bd #
G16
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Updated survival results of ALTER-C002: Anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer.
First Author: Yue Liu
Poster
2021 Gastrointestinal Cancers Symposium
Anlotinib combined with CAPEOX in first-line treatment of patients with RAS and BRAF wild-type unresectable metastatic colorectal cancer: A single-arm, phase II study (ALTER-C-002 trial).
First Author: Ke-Feng Ding
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: A multicenter, multicohort clinical trial (ALTER-G-001).
First Author: Jing Liu
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz